医学
心源性休克
内科学
心肌梗塞
心脏病学
临床终点
心力衰竭
经皮冠状动脉介入治疗
罪魁祸首
临床试验
作者
Matthias Böhme,Steffen Desch,Maciej Rosołowski,Markus Scholz,Knut Krohn,Petra Büttner,Michael Cross,Janine Kirchberg,Karl‐Philipp Rommel,Janine Pöss,Anne Freund,Ronny Baber,Berend Isermann,Uta Ceglarek,Klaus H. Metzeler,Uwe Platzbecker,Holger Thiele
标识
DOI:10.1016/j.jacc.2022.08.740
摘要
Clonal hematopoiesis of indeterminate potential (CHIP) is common in elderly individuals and is associated with an increased risk of both hematologic malignancies and cardiovascular disease. The impact of CHIP on the outcomes for patients with cardiogenic shock (CS) complicating acute myocardial infarction (AMI) remains undetermined.The purpose of this study was to determine the prognostic impact of CHIP in CS after AMI.Blood samples were obtained at randomization from 446 patients included in the CULPRIT-SHOCK (Culprit Lesion Only vs Multivessel Percutaneous Coronary Intervention in Cardiogenic Shock; NCT01927549) trial. CHIP was assessed using a next-generation sequencing approach targeting the most commonly mutated genes; the primary outcome at 30 days comprised all-cause mortality and renal replacement therapy.CHIP variants at ≥2% variant allele frequency were detected in 29% (n = 129), most commonly in the DNMT3A or TET2 genes, which harbored 47% and 36% of all mutations, respectively. Compared to non-CHIP patients, CHIP carriers were older and had decreased renal function and increased levels of N-terminal pro-B-type natriuretic peptide and inflammatory biomarkers. CHIP carriers had worse short-term outcomes measured either as mortality or as the combined clinical endpoint of mortality or severe renal failure within 30 days. Association of CHIP with the combined endpoint was independent of age and biomarkers reflecting kidney function, heart failure severity, and inflammation (OR: 1.83; 95% CI: 1.05-3.21; P = 0.03) but not significant regarding all-cause mortality (OR: 1.67; 95% CI: 0.96-2.90; P = 0.069).CHIP is frequent among AMI and CS patients and is associated with impaired clinical outcome. CHIP assessment may facilitate risk stratification in patients with CS and imply novel treatment targets. (Culprit Lesion Only vs Multivessel Percutaneous Coronary Intervention in Cardiogenic Shock [CULPRIT-SHOCK]; NCT01927549).
科研通智能强力驱动
Strongly Powered by AbleSci AI